State Street
BBOT

State Street’s BridgeBio Oncology BBOT Stock Holding History

State Street’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.9M Buy
1,036,569
+810,291
+358% +$6.76M ﹤0.01% 2809
2026
Q1 		$2.03M Buy
226,278
+8,000
+4% +$85.9K ﹤0.01% 3299
2025
Q4 		$2.73M Buy
218,278
+41,583
+24% +$504K ﹤0.01% 3234
2025
Q3 		$2.05M Buy
+176,695
New +$1.84M ﹤0.01% 3331

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street's BBOT Position: Q2 2026 in Review

State Street increased its BridgeBio Oncology (BBOT) stake by 358% in Q2 2026, buying an estimated $6.76M and bringing the position to 1,036,569 shares worth $7.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2809.

State Street first reported a position in BBOT in Q3 2025 and has held it in 4 quarters since. 57 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • State Street held 1,036,569 shares of BridgeBio Oncology worth $7.9M as of Q2 2026.
  • State Street bought 810,291 BridgeBio Oncology shares in Q2 2026, an estimated $6.76M.
  • BridgeBio Oncology made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2809 holding.
  • State Street first reported a position in BridgeBio Oncology in Q3 2025 and has held it in 4 quarters since.
  • 57 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.